NOX-6-18

CAS No. 898211-21-7

NOX-6-18( —— )

Catalog No. M37363 CAS No. 898211-21-7

NOX-6-18 (GPR132-B-160) is a highly potent and selective GPR132 antagonist with insulinotropic activity that modulates macrophage reprogramming in pancreatic islets and reduces weight gain.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 103 Get Quote
5MG 155 Get Quote
10MG 250 Get Quote
25MG 487 Get Quote
50MG 785 Get Quote
100MG 1224 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    NOX-6-18
  • Note
    Research use only, not for human use.
  • Brief Description
    NOX-6-18 (GPR132-B-160) is a highly potent and selective GPR132 antagonist with insulinotropic activity that modulates macrophage reprogramming in pancreatic islets and reduces weight gain.
  • Description
    GPR132 antagonist 1 (GPR132-B-160, Compound 25) is a GPR132 antagonist with an EC50 value of 0.075 μM. GPR132 antagonist 1 has promote insulin secretion activity with an EC50 value of 0.7 μM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    GPR
  • Recptor
    GPR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    898211-21-7
  • Formula Weight
    359.4
  • Molecular Formula
    C18H17NO5S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(O)C=1OC=2C=CC(=CC2C1C)S(=O)(=O)NCCC=3C=CC=CC3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • APD 668

    APD668 is a potent GPR119 agonist with EC50 of 2.7 nM and 33 nM for hGPR119 and ratGPR119 respectively.

  • BMS-903452

    BMS-903452 is a potent and selective GPR119 agonist with an EC50 of 14 nM, indicated for the treatment of acute and chronic rodent diabetes.

  • MBX2982

    MBX-2982 is a selective, orally-available GPR119 agonist for the treatment of type 2 tiabetes.